Condition (MeSH)
Neuromyelitis Optica
ClinicalTrials.gov lists 171 trials for Neuromyelitis Optica or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
171 of the 171 trials are tagged with Neuromyelitis Optica itself; the rest are tagged with a narrower condition beneath it.
When did Neuromyelitis Optica trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 20
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 19 |
| 2025 | 20 |
| 2024 | 19 |
| 2023 | 11 |
| 2022 | 19 |
| 2021 | 9 |
| 2020 | 12 |
| 2019 | 11 |
| 2018 | 6 |
| 2017 | 4 |
Showing 10 of 23 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 22 trials starting in 2026 and about 20 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 29 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 63 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neuromyelitis Optica trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 27 |
| Phase 1/2 | 12 |
| Phase 2 | 19 |
| Phase 2/3 | 8 |
| Phase 3 | 17 |
| Phase 4 | 10 |
| Not applicable | 17 |
| Observational | 61 |
How many Neuromyelitis Optica trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 17 |
| Recruiting | 46 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 11 |
| Completed | 52 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neuromyelitis Optica trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 9 |
| Hoffmann-La Roche | 5 |
| Amgen | 3 |
Which drugs are being tested for Neuromyelitis Optica? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| METHYLPREDNISOLONE | 8 |
| Inebilizumab | 7 |
| Satralizumab | 7 |
| RITUXIMAB | 6 |
| Eculizumab | 5 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Azathioprine Pill | 5 |
| IVMP | 3 |
| Plasma Exchange | 3 |
| Ofatumumab 300 | 2 |
| Eculizumab administration | 2 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neuromyelitis Optica trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neuromyelitis optica spectrum disorder | 54 | 4 |
| Urinary tract infection | 30 | 6 |
| Pneumonia | 26 | 7 |
| Cholecystitis acute | 11 | 4 |
| Influenza | 10 | 6 |
Showing 5 of 10 adverse events.
Which publications cover Neuromyelitis Optica? (140)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. | Neurology(R) neuroimmunology & neuroinflammation | 2025 | Yes |
| Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. | Multiple sclerosis and related disorders | 2025 | Yes |
| Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. | Journal of neurology, neurosurgery, and psychiatry | 2025 | Yes |
| Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. | Nature reviews. Neurology | 2025 | Yes |
| Research hotspots and emerging topics in neuromyelitis optica spectrum disorder treatment: Insights from a bibliometric analysis. | Medicine | 2025 | Yes |
Showing 5 of 140 publications.
Prevalence (93)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Neuromyelitis optica spectrum disorder | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Neuromyelitis optica spectrum disorder | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Neuromyelitis optica spectrum disorder | Annual incidence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Neuromyelitis optica spectrum disorder | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Neuromyelitis optica spectrum disorder | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
Showing 5 of 93 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Neuromyelitis optica spectrum disorder | 71211 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Neuromyelitis optica spectrum disorder | 71211 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.